← Back
Data updated: Jun 28, 2026
NEOS THERAPS INC
Pharma Pharmaceuticals
NEOS THERAPS INC is a pharmaceutical company with 4 FDA-approved products.
2012
Since
4
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
2 Small Molecules
NEOS THERAPS INC's Key Drugs
NEOS THERAPS INC's core commercial portfolio centers on ADZENYS XR-ODT, COTEMPLA XR-ODT — its most strategically important drugs approved in the last 15 years.
NEOS THERAPS INC's Recent FDA Approvals
New NDA/BLA approvals for NEOS THERAPS INC over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
NEOS THERAPS INC's Therapeutic Areas
Disease areas where NEOS THERAPS INC has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
NEOS THERAPS INC Pipeline Snapshot
Active clinical trials for NEOS THERAPS INC across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • ADZENYS XR-ODT leads revenue
- • 2 key drugs tracked
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (2)
Discontinued (2)
Company Info
- First Approval
- 2012-06-29
- Latest
- 2025-09-23
- Applications
- 4
FDA Sponsor Names
NEOS THERAPS INCNEOS THERAPS